ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global NSAIDs for Dysmenorrhea Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-36N11778
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global NSAIDs for Dysmenorrhea Market Research Report 2022
BUY CHAPTERS

Global NSAIDs for Dysmenorrhea Market Research Report 2025

Code: QYRE-Auto-36N11778
Report
February 2025
Pages:102
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
IOLCP
Granules Biocause
Strides Shasun
SI Group
Hisoar
Pfizer Inc
TEVA
Apotex
Lupin Ltd
Sanofi Aventis
Boehringer Ingelheim
BEC Chemicals
Shandong Xinhua Pharmaceutical
Hengrui Medicine
Hubei Biocause Heilen Pharmaceutical
Zibo Xinhua-Perrigo Pharmaceutical
Zhejiang Jiuzhou
Hubei Xunda
BASF AG
Mylan NV

NSAIDs for Dysmenorrhea Market Size

The global market for NSAIDs for Dysmenorrhea was valued at US$ 4316 million in the year 2024 and is projected to reach a revised size of US$ 6124 million by 2031, growing at a CAGR of 5.2% during the forecast period.

NSAIDs for Dysmenorrhea Market

NSAIDs for Dysmenorrhea Market

Diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen are the NSAIDs specifically approved by the US Food and Drug Administration (FDA) for treatment of dysmenorrhea.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for NSAIDs for Dysmenorrhea, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NSAIDs for Dysmenorrhea.
The NSAIDs for Dysmenorrhea market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global NSAIDs for Dysmenorrhea market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NSAIDs for Dysmenorrhea manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of NSAIDs for Dysmenorrhea Market Report

Report Metric Details
Report Name NSAIDs for Dysmenorrhea Market
Accounted market size in year US$ 4316 million
Forecasted market size in 2031 US$ 6124 million
CAGR 5.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Ibuprofen
  • Celecoxib
  • Ketoprofen
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company IOLCP, Granules Biocause, Strides Shasun, BASF, SI Group, Hisoar, Pfizer Inc, Teva, Mylan, Apotex, Lupin, SANOFI-Aventis, Boehringer-Ingelheim, BEC Chemicals, Shandong Xinhua Pharmaceutical, Hengrui Medicine, Hubei Biocause Heilen Pharmaceutical, Zibo Xinhua-PERRIGO Pharmaceutical, Zhejiang Jiuzhou, Hubei Xunda
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of NSAIDs for Dysmenorrhea manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of NSAIDs for Dysmenorrhea in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is NSAIDs for Dysmenorrhea Market growing?

Ans: The NSAIDs for Dysmenorrhea Market witnessing a CAGR of 5.2% during the forecast period 2025-2031.

What is the NSAIDs for Dysmenorrhea Market size in 2031?

Ans: The NSAIDs for Dysmenorrhea Market size in 2031 will be US$ 6124 million.

Who are the main players in the NSAIDs for Dysmenorrhea Market report?

Ans: The main players in the NSAIDs for Dysmenorrhea Market are IOLCP, Granules Biocause, Strides Shasun, BASF, SI Group, Hisoar, Pfizer Inc, Teva, Mylan, Apotex, Lupin, SANOFI-Aventis, Boehringer-Ingelheim, BEC Chemicals, Shandong Xinhua Pharmaceutical, Hengrui Medicine, Hubei Biocause Heilen Pharmaceutical, Zibo Xinhua-PERRIGO Pharmaceutical, Zhejiang Jiuzhou, Hubei Xunda

What are the Application segmentation covered in the NSAIDs for Dysmenorrhea Market report?

Ans: The Applications covered in the NSAIDs for Dysmenorrhea Market report are Hospital, Clinic, Pharmacy, Other

What are the Type segmentation covered in the NSAIDs for Dysmenorrhea Market report?

Ans: The Types covered in the NSAIDs for Dysmenorrhea Market report are Ibuprofen, Celecoxib, Ketoprofen, Others

1 NSAIDs for Dysmenorrhea Market Overview
1.1 Product Definition
1.2 NSAIDs for Dysmenorrhea by Type
1.2.1 Global NSAIDs for Dysmenorrhea Market Value Comparison by Type (2024 VS 2031)
1.2.2 Ibuprofen
1.2.3 Celecoxib
1.2.4 Ketoprofen
1.2.5 Others
1.3 NSAIDs for Dysmenorrhea by Application
1.3.1 Global NSAIDs for Dysmenorrhea Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Other
1.4 Global NSAIDs for Dysmenorrhea Market Size Estimates and Forecasts
1.4.1 Global NSAIDs for Dysmenorrhea Revenue 2020-2031
1.4.2 Global NSAIDs for Dysmenorrhea Sales 2020-2031
1.4.3 Global NSAIDs for Dysmenorrhea Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 NSAIDs for Dysmenorrhea Market Competition by Manufacturers
2.1 Global NSAIDs for Dysmenorrhea Sales Market Share by Manufacturers (2020-2025)
2.2 Global NSAIDs for Dysmenorrhea Revenue Market Share by Manufacturers (2020-2025)
2.3 Global NSAIDs for Dysmenorrhea Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of NSAIDs for Dysmenorrhea, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of NSAIDs for Dysmenorrhea, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of NSAIDs for Dysmenorrhea, Product Type & Application
2.7 Global Key Manufacturers of NSAIDs for Dysmenorrhea, Date of Enter into This Industry
2.8 Global NSAIDs for Dysmenorrhea Market Competitive Situation and Trends
2.8.1 Global NSAIDs for Dysmenorrhea Market Concentration Rate
2.8.2 The Global 5 and 10 Largest NSAIDs for Dysmenorrhea Players Market Share by Revenue
2.8.3 Global NSAIDs for Dysmenorrhea Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global NSAIDs for Dysmenorrhea Market Scenario by Region
3.1 Global NSAIDs for Dysmenorrhea Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global NSAIDs for Dysmenorrhea Sales by Region: 2020-2031
3.2.1 Global NSAIDs for Dysmenorrhea Sales by Region: 2020-2025
3.2.2 Global NSAIDs for Dysmenorrhea Sales by Region: 2026-2031
3.3 Global NSAIDs for Dysmenorrhea Revenue by Region: 2020-2031
3.3.1 Global NSAIDs for Dysmenorrhea Revenue by Region: 2020-2025
3.3.2 Global NSAIDs for Dysmenorrhea Revenue by Region: 2026-2031
3.4 North America NSAIDs for Dysmenorrhea Market Facts & Figures by Country
3.4.1 North America NSAIDs for Dysmenorrhea Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America NSAIDs for Dysmenorrhea Sales by Country (2020-2031)
3.4.3 North America NSAIDs for Dysmenorrhea Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe NSAIDs for Dysmenorrhea Market Facts & Figures by Country
3.5.1 Europe NSAIDs for Dysmenorrhea Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe NSAIDs for Dysmenorrhea Sales by Country (2020-2031)
3.5.3 Europe NSAIDs for Dysmenorrhea Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific NSAIDs for Dysmenorrhea Market Facts & Figures by Region
3.6.1 Asia Pacific NSAIDs for Dysmenorrhea Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific NSAIDs for Dysmenorrhea Sales by Region (2020-2031)
3.6.3 Asia Pacific NSAIDs for Dysmenorrhea Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America NSAIDs for Dysmenorrhea Market Facts & Figures by Country
3.7.1 Latin America NSAIDs for Dysmenorrhea Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America NSAIDs for Dysmenorrhea Sales by Country (2020-2031)
3.7.3 Latin America NSAIDs for Dysmenorrhea Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa NSAIDs for Dysmenorrhea Market Facts & Figures by Country
3.8.1 Middle East and Africa NSAIDs for Dysmenorrhea Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa NSAIDs for Dysmenorrhea Sales by Country (2020-2031)
3.8.3 Middle East and Africa NSAIDs for Dysmenorrhea Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global NSAIDs for Dysmenorrhea Sales by Type (2020-2031)
4.1.1 Global NSAIDs for Dysmenorrhea Sales by Type (2020-2025)
4.1.2 Global NSAIDs for Dysmenorrhea Sales by Type (2026-2031)
4.1.3 Global NSAIDs for Dysmenorrhea Sales Market Share by Type (2020-2031)
4.2 Global NSAIDs for Dysmenorrhea Revenue by Type (2020-2031)
4.2.1 Global NSAIDs for Dysmenorrhea Revenue by Type (2020-2025)
4.2.2 Global NSAIDs for Dysmenorrhea Revenue by Type (2026-2031)
4.2.3 Global NSAIDs for Dysmenorrhea Revenue Market Share by Type (2020-2031)
4.3 Global NSAIDs for Dysmenorrhea Price by Type (2020-2031)
5 Segment by Application
5.1 Global NSAIDs for Dysmenorrhea Sales by Application (2020-2031)
5.1.1 Global NSAIDs for Dysmenorrhea Sales by Application (2020-2025)
5.1.2 Global NSAIDs for Dysmenorrhea Sales by Application (2026-2031)
5.1.3 Global NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2031)
5.2 Global NSAIDs for Dysmenorrhea Revenue by Application (2020-2031)
5.2.1 Global NSAIDs for Dysmenorrhea Revenue by Application (2020-2025)
5.2.2 Global NSAIDs for Dysmenorrhea Revenue by Application (2026-2031)
5.2.3 Global NSAIDs for Dysmenorrhea Revenue Market Share by Application (2020-2031)
5.3 Global NSAIDs for Dysmenorrhea Price by Application (2020-2031)
6 Key Companies Profiled
6.1 IOLCP
6.1.1 IOLCP Company Information
6.1.2 IOLCP Description and Business Overview
6.1.3 IOLCP NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.1.4 IOLCP NSAIDs for Dysmenorrhea Product Portfolio
6.1.5 IOLCP Recent Developments/Updates
6.2 Granules Biocause
6.2.1 Granules Biocause Company Information
6.2.2 Granules Biocause Description and Business Overview
6.2.3 Granules Biocause NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Granules Biocause NSAIDs for Dysmenorrhea Product Portfolio
6.2.5 Granules Biocause Recent Developments/Updates
6.3 Strides Shasun
6.3.1 Strides Shasun Company Information
6.3.2 Strides Shasun Description and Business Overview
6.3.3 Strides Shasun NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Strides Shasun NSAIDs for Dysmenorrhea Product Portfolio
6.3.5 Strides Shasun Recent Developments/Updates
6.4 BASF
6.4.1 BASF Company Information
6.4.2 BASF Description and Business Overview
6.4.3 BASF NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.4.4 BASF NSAIDs for Dysmenorrhea Product Portfolio
6.4.5 BASF Recent Developments/Updates
6.5 SI Group
6.5.1 SI Group Company Information
6.5.2 SI Group Description and Business Overview
6.5.3 SI Group NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.5.4 SI Group NSAIDs for Dysmenorrhea Product Portfolio
6.5.5 SI Group Recent Developments/Updates
6.6 Hisoar
6.6.1 Hisoar Company Information
6.6.2 Hisoar Description and Business Overview
6.6.3 Hisoar NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Hisoar NSAIDs for Dysmenorrhea Product Portfolio
6.6.5 Hisoar Recent Developments/Updates
6.7 Pfizer Inc
6.7.1 Pfizer Inc Company Information
6.7.2 Pfizer Inc Description and Business Overview
6.7.3 Pfizer Inc NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Inc NSAIDs for Dysmenorrhea Product Portfolio
6.7.5 Pfizer Inc Recent Developments/Updates
6.8 Teva
6.8.1 Teva Company Information
6.8.2 Teva Description and Business Overview
6.8.3 Teva NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Teva NSAIDs for Dysmenorrhea Product Portfolio
6.8.5 Teva Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Company Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Mylan NSAIDs for Dysmenorrhea Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Apotex
6.10.1 Apotex Company Information
6.10.2 Apotex Description and Business Overview
6.10.3 Apotex NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Apotex NSAIDs for Dysmenorrhea Product Portfolio
6.10.5 Apotex Recent Developments/Updates
6.11 Lupin
6.11.1 Lupin Company Information
6.11.2 Lupin Description and Business Overview
6.11.3 Lupin NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Lupin NSAIDs for Dysmenorrhea Product Portfolio
6.11.5 Lupin Recent Developments/Updates
6.12 SANOFI-Aventis
6.12.1 SANOFI-Aventis Company Information
6.12.2 SANOFI-Aventis Description and Business Overview
6.12.3 SANOFI-Aventis NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.12.4 SANOFI-Aventis NSAIDs for Dysmenorrhea Product Portfolio
6.12.5 SANOFI-Aventis Recent Developments/Updates
6.13 Boehringer-Ingelheim
6.13.1 Boehringer-Ingelheim Company Information
6.13.2 Boehringer-Ingelheim Description and Business Overview
6.13.3 Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Boehringer-Ingelheim NSAIDs for Dysmenorrhea Product Portfolio
6.13.5 Boehringer-Ingelheim Recent Developments/Updates
6.14 BEC Chemicals
6.14.1 BEC Chemicals Company Information
6.14.2 BEC Chemicals Description and Business Overview
6.14.3 BEC Chemicals NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.14.4 BEC Chemicals NSAIDs for Dysmenorrhea Product Portfolio
6.14.5 BEC Chemicals Recent Developments/Updates
6.15 Shandong Xinhua Pharmaceutical
6.15.1 Shandong Xinhua Pharmaceutical Company Information
6.15.2 Shandong Xinhua Pharmaceutical Description and Business Overview
6.15.3 Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolio
6.15.5 Shandong Xinhua Pharmaceutical Recent Developments/Updates
6.16 Hengrui Medicine
6.16.1 Hengrui Medicine Company Information
6.16.2 Hengrui Medicine Description and Business Overview
6.16.3 Hengrui Medicine NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Hengrui Medicine NSAIDs for Dysmenorrhea Product Portfolio
6.16.5 Hengrui Medicine Recent Developments/Updates
6.17 Hubei Biocause Heilen Pharmaceutical
6.17.1 Hubei Biocause Heilen Pharmaceutical Company Information
6.17.2 Hubei Biocause Heilen Pharmaceutical Description and Business Overview
6.17.3 Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolio
6.17.5 Hubei Biocause Heilen Pharmaceutical Recent Developments/Updates
6.18 Zibo Xinhua-PERRIGO Pharmaceutical
6.18.1 Zibo Xinhua-PERRIGO Pharmaceutical Company Information
6.18.2 Zibo Xinhua-PERRIGO Pharmaceutical Description and Business Overview
6.18.3 Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Product Portfolio
6.18.5 Zibo Xinhua-PERRIGO Pharmaceutical Recent Developments/Updates
6.19 Zhejiang Jiuzhou
6.19.1 Zhejiang Jiuzhou Company Information
6.19.2 Zhejiang Jiuzhou Description and Business Overview
6.19.3 Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Product Portfolio
6.19.5 Zhejiang Jiuzhou Recent Developments/Updates
6.20 Hubei Xunda
6.20.1 Hubei Xunda Company Information
6.20.2 Hubei Xunda Description and Business Overview
6.20.3 Hubei Xunda NSAIDs for Dysmenorrhea Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Hubei Xunda NSAIDs for Dysmenorrhea Product Portfolio
6.20.5 Hubei Xunda Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 NSAIDs for Dysmenorrhea Industry Chain Analysis
7.2 NSAIDs for Dysmenorrhea Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 NSAIDs for Dysmenorrhea Production Mode & Process Analysis
7.4 NSAIDs for Dysmenorrhea Sales and Marketing
7.4.1 NSAIDs for Dysmenorrhea Sales Channels
7.4.2 NSAIDs for Dysmenorrhea Distributors
7.5 NSAIDs for Dysmenorrhea Customer Analysis
8 NSAIDs for Dysmenorrhea Market Dynamics
8.1 NSAIDs for Dysmenorrhea Industry Trends
8.2 NSAIDs for Dysmenorrhea Market Drivers
8.3 NSAIDs for Dysmenorrhea Market Challenges
8.4 NSAIDs for Dysmenorrhea Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
IOLCP
Granules Biocause
Strides Shasun
SI Group
Hisoar
Pfizer Inc
TEVA
Apotex
Lupin Ltd
Sanofi Aventis
Boehringer Ingelheim
BEC Chemicals
Shandong Xinhua Pharmaceutical
Hengrui Medicine
Hubei Biocause Heilen Pharmaceutical
Zibo Xinhua-Perrigo Pharmaceutical
Zhejiang Jiuzhou
Hubei Xunda
BASF AG
Mylan NV
List of Tables
 Table 1. Global NSAIDs for Dysmenorrhea Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global NSAIDs for Dysmenorrhea Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global NSAIDs for Dysmenorrhea Market Competitive Situation by Manufacturers in 2024
 Table 4. Global NSAIDs for Dysmenorrhea Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global NSAIDs for Dysmenorrhea Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global NSAIDs for Dysmenorrhea Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global NSAIDs for Dysmenorrhea Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market NSAIDs for Dysmenorrhea Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of NSAIDs for Dysmenorrhea, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of NSAIDs for Dysmenorrhea, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of NSAIDs for Dysmenorrhea, Product Type & Application
 Table 12. Global Key Manufacturers of NSAIDs for Dysmenorrhea, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global NSAIDs for Dysmenorrhea by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NSAIDs for Dysmenorrhea as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global NSAIDs for Dysmenorrhea Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global NSAIDs for Dysmenorrhea Sales by Region (2020-2025) & (K Units)
 Table 18. Global NSAIDs for Dysmenorrhea Sales Market Share by Region (2020-2025)
 Table 19. Global NSAIDs for Dysmenorrhea Sales by Region (2026-2031) & (K Units)
 Table 20. Global NSAIDs for Dysmenorrhea Sales Market Share by Region (2026-2031)
 Table 21. Global NSAIDs for Dysmenorrhea Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global NSAIDs for Dysmenorrhea Revenue Market Share by Region (2020-2025)
 Table 23. Global NSAIDs for Dysmenorrhea Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global NSAIDs for Dysmenorrhea Revenue Market Share by Region (2026-2031)
 Table 25. North America NSAIDs for Dysmenorrhea Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
 Table 27. North America NSAIDs for Dysmenorrhea Sales by Country (2026-2031) & (K Units)
 Table 28. North America NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America NSAIDs for Dysmenorrhea Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe NSAIDs for Dysmenorrhea Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
 Table 32. Europe NSAIDs for Dysmenorrhea Sales by Country (2026-2031) & (K Units)
 Table 33. Europe NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe NSAIDs for Dysmenorrhea Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific NSAIDs for Dysmenorrhea Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific NSAIDs for Dysmenorrhea Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific NSAIDs for Dysmenorrhea Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific NSAIDs for Dysmenorrhea Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific NSAIDs for Dysmenorrhea Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America NSAIDs for Dysmenorrhea Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America NSAIDs for Dysmenorrhea Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America NSAIDs for Dysmenorrhea Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa NSAIDs for Dysmenorrhea Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa NSAIDs for Dysmenorrhea Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa NSAIDs for Dysmenorrhea Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa NSAIDs for Dysmenorrhea Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa NSAIDs for Dysmenorrhea Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global NSAIDs for Dysmenorrhea Sales (K Units) by Type (2020-2025)
 Table 51. Global NSAIDs for Dysmenorrhea Sales (K Units) by Type (2026-2031)
 Table 52. Global NSAIDs for Dysmenorrhea Sales Market Share by Type (2020-2025)
 Table 53. Global NSAIDs for Dysmenorrhea Sales Market Share by Type (2026-2031)
 Table 54. Global NSAIDs for Dysmenorrhea Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global NSAIDs for Dysmenorrhea Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global NSAIDs for Dysmenorrhea Revenue Market Share by Type (2020-2025)
 Table 57. Global NSAIDs for Dysmenorrhea Revenue Market Share by Type (2026-2031)
 Table 58. Global NSAIDs for Dysmenorrhea Price (US$/Unit) by Type (2020-2025)
 Table 59. Global NSAIDs for Dysmenorrhea Price (US$/Unit) by Type (2026-2031)
 Table 60. Global NSAIDs for Dysmenorrhea Sales (K Units) by Application (2020-2025)
 Table 61. Global NSAIDs for Dysmenorrhea Sales (K Units) by Application (2026-2031)
 Table 62. Global NSAIDs for Dysmenorrhea Sales Market Share by Application (2020-2025)
 Table 63. Global NSAIDs for Dysmenorrhea Sales Market Share by Application (2026-2031)
 Table 64. Global NSAIDs for Dysmenorrhea Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global NSAIDs for Dysmenorrhea Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global NSAIDs for Dysmenorrhea Revenue Market Share by Application (2020-2025)
 Table 67. Global NSAIDs for Dysmenorrhea Revenue Market Share by Application (2026-2031)
 Table 68. Global NSAIDs for Dysmenorrhea Price (US$/Unit) by Application (2020-2025)
 Table 69. Global NSAIDs for Dysmenorrhea Price (US$/Unit) by Application (2026-2031)
 Table 70. IOLCP Company Information
 Table 71. IOLCP Description and Business Overview
 Table 72. IOLCP NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. IOLCP NSAIDs for Dysmenorrhea Product
 Table 74. IOLCP Recent Developments/Updates
 Table 75. Granules Biocause Company Information
 Table 76. Granules Biocause Description and Business Overview
 Table 77. Granules Biocause NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Granules Biocause NSAIDs for Dysmenorrhea Product
 Table 79. Granules Biocause Recent Developments/Updates
 Table 80. Strides Shasun Company Information
 Table 81. Strides Shasun Description and Business Overview
 Table 82. Strides Shasun NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Strides Shasun NSAIDs for Dysmenorrhea Product
 Table 84. Strides Shasun Recent Developments/Updates
 Table 85. BASF Company Information
 Table 86. BASF Description and Business Overview
 Table 87. BASF NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. BASF NSAIDs for Dysmenorrhea Product
 Table 89. BASF Recent Developments/Updates
 Table 90. SI Group Company Information
 Table 91. SI Group Description and Business Overview
 Table 92. SI Group NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. SI Group NSAIDs for Dysmenorrhea Product
 Table 94. SI Group Recent Developments/Updates
 Table 95. Hisoar Company Information
 Table 96. Hisoar Description and Business Overview
 Table 97. Hisoar NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Hisoar NSAIDs for Dysmenorrhea Product
 Table 99. Hisoar Recent Developments/Updates
 Table 100. Pfizer Inc Company Information
 Table 101. Pfizer Inc Description and Business Overview
 Table 102. Pfizer Inc NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Pfizer Inc NSAIDs for Dysmenorrhea Product
 Table 104. Pfizer Inc Recent Developments/Updates
 Table 105. Teva Company Information
 Table 106. Teva Description and Business Overview
 Table 107. Teva NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Teva NSAIDs for Dysmenorrhea Product
 Table 109. Teva Recent Developments/Updates
 Table 110. Mylan Company Information
 Table 111. Mylan Description and Business Overview
 Table 112. Mylan NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Mylan NSAIDs for Dysmenorrhea Product
 Table 114. Mylan Recent Developments/Updates
 Table 115. Apotex Company Information
 Table 116. Apotex Description and Business Overview
 Table 117. Apotex NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Apotex NSAIDs for Dysmenorrhea Product
 Table 119. Apotex Recent Developments/Updates
 Table 120. Lupin Company Information
 Table 121. Lupin Description and Business Overview
 Table 122. Lupin NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Lupin NSAIDs for Dysmenorrhea Product
 Table 124. Lupin Recent Developments/Updates
 Table 125. SANOFI-Aventis Company Information
 Table 126. SANOFI-Aventis Description and Business Overview
 Table 127. SANOFI-Aventis NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. SANOFI-Aventis NSAIDs for Dysmenorrhea Product
 Table 129. SANOFI-Aventis Recent Developments/Updates
 Table 130. Boehringer-Ingelheim Company Information
 Table 131. Boehringer-Ingelheim Description and Business Overview
 Table 132. Boehringer-Ingelheim NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Boehringer-Ingelheim NSAIDs for Dysmenorrhea Product
 Table 134. Boehringer-Ingelheim Recent Developments/Updates
 Table 135. BEC Chemicals Company Information
 Table 136. BEC Chemicals Description and Business Overview
 Table 137. BEC Chemicals NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. BEC Chemicals NSAIDs for Dysmenorrhea Product
 Table 139. BEC Chemicals Recent Developments/Updates
 Table 140. Shandong Xinhua Pharmaceutical Company Information
 Table 141. Shandong Xinhua Pharmaceutical Description and Business Overview
 Table 142. Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Shandong Xinhua Pharmaceutical NSAIDs for Dysmenorrhea Product
 Table 144. Shandong Xinhua Pharmaceutical Recent Developments/Updates
 Table 145. Hengrui Medicine Company Information
 Table 146. Hengrui Medicine Description and Business Overview
 Table 147. Hengrui Medicine NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. Hengrui Medicine NSAIDs for Dysmenorrhea Product
 Table 149. Hengrui Medicine Recent Developments/Updates
 Table 150. Hubei Biocause Heilen Pharmaceutical Company Information
 Table 151. Hubei Biocause Heilen Pharmaceutical Description and Business Overview
 Table 152. Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Hubei Biocause Heilen Pharmaceutical NSAIDs for Dysmenorrhea Product
 Table 154. Hubei Biocause Heilen Pharmaceutical Recent Developments/Updates
 Table 155. Zibo Xinhua-PERRIGO Pharmaceutical Company Information
 Table 156. Zibo Xinhua-PERRIGO Pharmaceutical Description and Business Overview
 Table 157. Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. Zibo Xinhua-PERRIGO Pharmaceutical NSAIDs for Dysmenorrhea Product
 Table 159. Zibo Xinhua-PERRIGO Pharmaceutical Recent Developments/Updates
 Table 160. Zhejiang Jiuzhou Company Information
 Table 161. Zhejiang Jiuzhou Description and Business Overview
 Table 162. Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. Zhejiang Jiuzhou NSAIDs for Dysmenorrhea Product
 Table 164. Zhejiang Jiuzhou Recent Developments/Updates
 Table 165. Hubei Xunda Company Information
 Table 166. Hubei Xunda Description and Business Overview
 Table 167. Hubei Xunda NSAIDs for Dysmenorrhea Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 168. Hubei Xunda NSAIDs for Dysmenorrhea Product
 Table 169. Hubei Xunda Recent Developments/Updates
 Table 170. Key Raw Materials Lists
 Table 171. Raw Materials Key Suppliers Lists
 Table 172. NSAIDs for Dysmenorrhea Distributors List
 Table 173. NSAIDs for Dysmenorrhea Customers List
 Table 174. NSAIDs for Dysmenorrhea Market Trends
 Table 175. NSAIDs for Dysmenorrhea Market Drivers
 Table 176. NSAIDs for Dysmenorrhea Market Challenges
 Table 177. NSAIDs for Dysmenorrhea Market Restraints
 Table 178. Research Programs/Design for This Report
 Table 179. Key Data Information from Secondary Sources
 Table 180. Key Data Information from Primary Sources
 Table 181. Authors List of This Report


List of Figures
 Figure 1. Product Picture of NSAIDs for Dysmenorrhea
 Figure 2. Global NSAIDs for Dysmenorrhea Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global NSAIDs for Dysmenorrhea Market Share by Type: 2024 & 2031
 Figure 4. Ibuprofen Product Picture
 Figure 5. Celecoxib Product Picture
 Figure 6. Ketoprofen Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global NSAIDs for Dysmenorrhea Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global NSAIDs for Dysmenorrhea Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Pharmacy
 Figure 13. Other
 Figure 14. Global NSAIDs for Dysmenorrhea Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global NSAIDs for Dysmenorrhea Market Size (2020-2031) & (US$ Million)
 Figure 16. Global NSAIDs for Dysmenorrhea Sales (2020-2031) & (K Units)
 Figure 17. Global NSAIDs for Dysmenorrhea Average Price (US$/Unit) & (2020-2031)
 Figure 18. NSAIDs for Dysmenorrhea Report Years Considered
 Figure 19. NSAIDs for Dysmenorrhea Sales Share by Manufacturers in 2024
 Figure 20. Global NSAIDs for Dysmenorrhea Revenue Share by Manufacturers in 2024
 Figure 21. Global 5 and 10 Largest NSAIDs for Dysmenorrhea Players: Market Share by Revenue in NSAIDs for Dysmenorrhea in 2024
 Figure 22. NSAIDs for Dysmenorrhea Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 23. Global NSAIDs for Dysmenorrhea Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 24. North America NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2031)
 Figure 25. North America NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2031)
 Figure 26. United States NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Canada NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Europe NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2031)
 Figure 29. Europe NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2031)
 Figure 30. Germany NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. France NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. U.K. NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Italy NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Russia NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Asia Pacific NSAIDs for Dysmenorrhea Sales Market Share by Region (2020-2031)
 Figure 36. Asia Pacific NSAIDs for Dysmenorrhea Revenue Market Share by Region (2020-2031)
 Figure 37. China NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Japan NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. South Korea NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. India NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Australia NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. China Taiwan NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Indonesia NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Thailand NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Malaysia NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2031)
 Figure 47. Latin America NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa NSAIDs for Dysmenorrhea Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa NSAIDs for Dysmenorrhea Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE NSAIDs for Dysmenorrhea Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of NSAIDs for Dysmenorrhea by Type (2020-2031)
 Figure 57. Global Revenue Market Share of NSAIDs for Dysmenorrhea by Type (2020-2031)
 Figure 58. Global NSAIDs for Dysmenorrhea Price (US$/Unit) by Type (2020-2031)
 Figure 59. Global Sales Market Share of NSAIDs for Dysmenorrhea by Application (2020-2031)
 Figure 60. Global Revenue Market Share of NSAIDs for Dysmenorrhea by Application (2020-2031)
 Figure 61. Global NSAIDs for Dysmenorrhea Price (US$/Unit) by Application (2020-2031)
 Figure 62. NSAIDs for Dysmenorrhea Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Ibuprofen Sodium​ API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-30X13296
Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Enteric Gelatin Hollow Capsule Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-11U13426
Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Tranexamic Acid Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-17W7451
Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Moxifloxacin HCl Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

120 Pages
Type: Report
Code: QYRE-Auto-13144
Fri Mar 21 00:00:00 UTC 2025

$8000

Enterprise User

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions